Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study

PURPOSE: Sunitinib is an oral tyrosine kinase inhibitor of VEGF, PDGF, c-KIT, and flt-3 receptors. A pediatric phase I study of sunitinib capsules identified the maximum tolerated dose as 15 mg/m(2)/day. This study was conducted to evaluate sunitinib given as a powder formulation. METHODS: Sunitinib...

詳細記述

保存先:
書誌詳細
主要な著者: DuBois, Steven G., Shusterman, Suzanne, Reid, Joel M., Ingle, Ashish M., Ahern, Charlotte H., Baruchel, Sylvain, Glade-Bender, Julia, Ivy, Percy, Adamson, Peter C., Blaney, Susan M.
フォーマット: Artigo
言語:Inglês
出版事項: 2011
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4008320/
https://ncbi.nlm.nih.gov/pubmed/22179104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-011-1798-2
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料